Stockreport

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]

Vir Biotechnology, Inc.  (VIR) 
PDF therapy, 100% (6/6) of participants had HDV RNA less than the lower limit of quantification – – Phase 2 SOLSTICE trial on track to complete enrollment ahead of schedul [Read more]